Tokyo Tape
Sign in
← Kirin Holdings

Quarterly report · Q1

2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥501.8bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.13T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥450.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥30.8bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥11.0bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥44.2bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥197.0bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥20.1bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥25.9bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥5.6bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥32.6bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥11.3bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.00Tat 2024-03-31Cons.Assets IFRS
Total assets¥2.87Tat 2023-12-31Cons.Assets IFRS
Total assets¥2.47Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.55Tat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥1.44Tat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥1.46Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.43Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.23Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.25Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥1.16Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.13Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥971.9bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥151.2bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥131.4bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥116.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.1bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥39.9bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥203.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥41.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥65.3bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥226.1bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.4bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥34.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥35.9bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥8.6bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥31.982024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥139.162023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥6.92023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥31.982024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥139.152023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥6.92023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio38.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.5%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio39.4%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥20.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥4.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥15.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31−¥158m
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥17.2bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥17.2bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥12.3bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-03-31¥238.6bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-03-31¥238.2bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥379m
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-03-31¥18.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue2024-01-01 → 2024-03-31¥32.7bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue external2024-01-01 → 2024-03-31¥31.9bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥726m
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentsegment profit2024-01-01 → 2024-03-31−¥1.7bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2024-01-01 → 2024-03-31¥122.2bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2024-01-01 → 2024-03-31¥121.5bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥645m
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2024-01-01 → 2024-03-31¥12.2bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥105.6bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥105.5bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥67m
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥22.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥6.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥16.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31−¥265m
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥18.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥18.0bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥11.5bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-03-31¥225.4bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-03-31¥225.1bn
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥300m
jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-03-31¥20.9bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue2023-01-01 → 2023-03-31¥18.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue external2023-01-01 → 2023-03-31¥17.4bn
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥991m
jpcrp040300-q1r_E00395-000Health Sciencereportable segmentsegment profit2023-01-01 → 2023-03-31−¥1.4bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue2023-01-01 → 2023-03-31¥108.6bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue external2023-01-01 → 2023-03-31¥108.0bn
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥609m
jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segmentsegment profit2023-01-01 → 2023-03-31¥9.6bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥93.5bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥93.4bn
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥107m
jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥16.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 779
ItemContextValueUnit
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-4641000000JPY
Other comprehensive income IFRSPrior1YTDDuration23156000000JPY
Other comprehensive income IFRSCurrentYTDDuration43137000000JPY
Comprehensive income IFRSPrior1YTDDuration34482000000JPY
Comprehensive income IFRSCurrentYTDDuration75723000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration26073000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration61628000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration8409000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration14096000000JPY
Comprehensive income IFRSPrior1YTDDuration34482000000JPY
Comprehensive income IFRSCurrentYTDDuration75723000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember102046000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember25519000000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember1063823000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-251788000000JPY
Equity IFRSPrior2YearInstant_NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember16826000000JPY
Equity IFRSPrior2YearInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember5591000000JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember2668000000JPY
Other comprehensive income IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember-1476000000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember5591000000JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember2668000000JPY
Comprehensive income IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember-1476000000JPY
Dividends ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-29559000000JPY
Dividends ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-4000000JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-0JPY
Disposal of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass